Company news_innoModel-Provide preclinical pharmacological services

Cn /En

News Center

——

Company news

Industry news

04-12

InnoModels Biotechnology: Introduction to the main features of the in vivo tumor experimental platform

In the field of biomedicine, tumor research has always been an important topic for researchers. With the development of science and technology, experimental platforms are constantly upgraded to meet the needs of more accurate and faster research. The in vivo tumor experimental platform of InnoModels Biotechnology is one of the leaders, which leads the new direction of tumor research with its unique features

04-11

InnoModels Biotechnology: Features of the preclinical evaluation platform for tumor vaccines

With the continuous advancement of cancer treatment, tumor vaccines, as an emerging means of immunotherapy, have received widespread attention. However, the development and evaluation of tumor vaccines require highly specialized platforms to ensure the accuracy and reliability of their experimental data. The InnoModels Biotechnology tumor vaccine preclinical evaluation platform was born to meet this need, and it provides powerful support and tools for tumor vaccine development with its unique features.

04-11

InnoModels Biotechnology: What are the main advantages of the MHC humanized mouse model?

With the deepening of biomedical research, there is an increasing need for scientists to study the occurrence, development and treatment strategies of diseases. In this process, animal models play an irreplaceable role as important experimental tools. Among them, InnoModels Biotechnology MHC humanized mouse model has become a star model in the field of biomedical research with its unique advantages

04-10

InnoModels Biotechnology: PBMC-OncVax Tumor Vaccine Model

In the field of cancer immunotherapy, vaccines are gaining attention as a strategy to stimulate the body's own immune system to fight against tumors. The PBMC-OncVax tumor vaccine model developed by InnoModels Biotechnology provides a powerful tool for tumor vaccine research and development by virtue of its unique advantages and innovative capabilities. Highly personalized tumor vaccine design: The PBMC-OncVax model uses the patient's own peripheral blood mononuclear cells (PBMCs), ensuring a highly personalized vaccine. These cells, after specific genetic modifications and exposure to tumor-associated antigens, are able to train the immune system to recognize and attack specific tumor cells, tailoring the most appropriate tumor vaccine for each patient.

< 1...29 30 31...61 >

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License